To further investigate the therapeutic benefit of BBR in combination with TRAIL-targeted therapy, the adjuvant effect of BBR with an agonistic TRAIL-receptor anti-DR5 antibody (MD5-1) treatment was analyzed in the murine 4T1 breast cancer model. The gene discussed is TNFRSF10B; the disease is breast cancer.